The Mini-MD, ISO13485 workshops, and Product Commercialisation: Life After the Prototype
Ogan and Ee Bin spent the week of February 20-24 – right towards the tail end of summer in Auckland, New Zealand, to deliver the Mini-MD, the ISO13485 workshops, and a couple of lunchtime sessions on product commercialisation.
With generally clear skies and temperatures between 17-25 degrees centigrade, what more can you ask for?
Well, perhaps to conduct the courses outdoors? 🙂
The “Mini-MD” – here for the first time in New Zealand
The Mini-MD is a comprehensive, intensive overview of all of medicine presented in two days and designed for healthcare professionals without formal medical training. It covers the basic, preclinical and clinical sciences, emphasizing the main principles and logic of medicine, how doctors think, and how the healthcare system works.
For the first time in New Zealand, Ogan Gurel, MD, came to this gorgeous country of New Zealand to deliver the “Mini-MD”
Here are what some participants have to say..
Bruce Moller, CEO at Howard Wright Limited
Ogan’s two day Mini-MD is an outstanding course. Ogan is first rate presenter and his fast paced course is engaging, energizing and inspiring. The Mini-MD puts you in the shoes of a MD, gives you an overview of their training and provides you with a foundation for further understanding and effective communication with clinicians
Enrico Tronchin, Senior Commercialisation Manager at AUT Enterprises Ltd.
Ogan is a great guy with a remarkable depth and breadth of understanding of the whole of medicine. His MiniMD course provided me a very immersive, intensive and broad experience of medicine which will help me engage better with people in the medical and health sector. I have an improved understanding of the way people speak and think in this complex environment in which I seek to commercialise new technology. Many thanks, Ogan!
Explaining ISO13485 and Being Audit-Ready
It’s been a year since the ISO13485:2016 had been released – and our third class conducted in New Zealand (one in ChristChurch and two in Auckland). Thus the transition deadline gets closer and companies are getting caught with challenging financial decisions on their re-certification processes.
Especially the companies getting re-certified around the later part of 2017..
“should we get re-certified now to 2003 version, then get certified again in 2019 for the 2016 version?”
” or should we just shoot for the 2016 version right now?”
“how much will my certification company charge me?”
there were also questions on the actual dates of implementation.
“is it really March 2017? what happens after that?”
All these aside, the same questions arised with regards to supplier controls, regulatory requirements, risk management, and software validation.
Was a small class, as usual, but with these setups, is big on value and especially group discussions.
Access-2-Healthcare should be holding one more class either towards the end of this year or March 2018. So watch this space!
Product Commercialisation in the Medical Technology Industry – Life after the Prototype
In that week, we also presented to two groups of folks within AUT about the challenges in product commericalisation in the healthcare/medical technology industry. Most of the attendees were researchers in AUT and they gained knowledge beyond the prototyping, and licensing, into the tough and difficult process of taking the product to the market and reaching the end-users’ hands.
One of the significant concepts shared was about the synchronisation of marketing, regulatory, intellectual property and clinical activities together. Too often are these aspects taken in isolation and the interdependency is often ignored, thus impacting the expenditure of the orgnisation unnecessarily.
All of the activities would not have been possible without the great support of the Auckland University of Technology, and AUT Enterprises Limited (AUTEL), and AUT Events in particular. Special Thanks to Enrico Tronchin would have done heaps to enable all of the above to be turned into a reality, which in turn enabled the NZ healthcare indsutry tske another step forward. Cheers!
